Compare — Georgia Financials

panel 2026-09-21Ask

Pooled trend

5 companies

Aggregate by year

GEL, thousands · money Σ · ratios from summed bases · growth on the pooled series

Metric	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Revenue	125,552	147,403	176,776	202,574	264,328	280,468	342,769	605,439
EBITDA	39,564	30,565	36,135	49,223	74,027	74,538	75,497	229,120
Net profit	14,791	25,828	29,846	45,170	57,350	44,992	58,734	224,822
Total assets	135,707	154,009	178,873	223,495	266,782	283,906	409,754	691,698
n (companies reporting)	4	4	4	4	4	4	5	5

Per-company contribution by year

XLSX

GEL, thousands

Company	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024
Shotapharm	—	—	—	—	—	—	127,232	327,423
GM Pharmaceuticals	94,259	105,923	123,065	135,929	183,285	191,099	130,729	184,906
Aversi-Rational	31,294	22,626	33,693	39,215	51,337	58,499	59,765	63,771
Neoparmi	0	11,787	13,399	16,583	16,848	18,458	15,356	19,189
Bioparmi	0	7,068	6,619	10,847	12,858	12,412	9,686	10,150

Rows are the raw pool — every peer, including any excluded from the sums above, so the de-duplication stays auditable. Tinted cells are the excluded company-years.

Peer coverage varies by year — FY2017–FY2022 pool fewer than the 5 picked companies (see the n row). A year is never dropped because one peer is missing.

Pooled figures sum every peer in the set. Known parent/subsidiary groups that file separately are de-duplicated; groups not yet curated may still be counted more than once.